Overview

Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Chemotherapy is an important therapeutic method for unresectable gastric cancer patients. However, there is currently no established standard chemotherapeutic regimen for gastric cancer. The aim of our study was to compare the efficacy and toxicity between SEEOX and SOX regimens. The investigators estimate that combined intravenous and intra-arterial intensified SEEOX neoadjuvant chemotherapy may be a safe and promising regimen in unresectable gastric cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Jinling Hospital, China
Treatments:
Epirubicin
Etoposide
Etoposide phosphate
Oxaliplatin